Jan Buitelaar
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jan Buitelaar.
American Journal of Psychiatry | 2013
Edmund Sonuga-Barke; Daniel Brandeis; Samuele Cortese; David Daley; Maite Ferrin; Martin Holtmann; Jim Stevenson; Marina Danckaerts; Saskia Van der Oord; Manfred Döpfner; Ralf W. Dittmann; Emily Simonoff; Alessandro Zuddas; Tobias Banaschewski; Jan Buitelaar; David Coghill; Chris Hollis; Eric Konofal; Michel Lecendreux; Ian C. K. Wong; Joseph A. Sergeant
OBJECTIVEnNonpharmacological treatments are available for attention deficit hyperactivity disorder (ADHD), although their efficacy remains uncertain. The authors undertook meta-analyses of the efficacy of dietary (restricted elimination diets, artificial food color exclusions, and free fatty acid supplementation) and psychological (cognitive training, neurofeedback, and behavioral interventions) ADHD treatments.nnnMETHODnUsing a common systematic search and a rigorous coding and data extraction strategy across domains, the authors searched electronic databases to identify published randomized controlled trials that involved individuals who were diagnosed with ADHD (or who met a validated cutoff on a recognized rating scale) and that included an ADHD outcome.nnnRESULTSnFifty-four of the 2,904 nonduplicate screened records were included in the analyses. Two different analyses were performed. When the outcome measure was based on ADHD assessments by raters closest to the therapeutic setting, all dietary (standardized mean differences=0.21-0.48) and psychological (standardized mean differences=0.40-0.64) treatments produced statistically significant effects. However, when the best probably blinded assessment was employed, effects remained significant for free fatty acid supplementation (standardized mean difference=0.16) and artificial food color exclusion (standardized mean difference=0.42) but were substantially attenuated to nonsignificant levels for other treatments.nnnCONCLUSIONSnFree fatty acid supplementation produced small but significant reductions in ADHD symptoms even with probably blinded assessments, although the clinical significance of these effects remains to be determined. Artificial food color exclusion produced larger effects but often in individuals selected for food sensitivities. Better evidence for efficacy from blinded assessments is required for behavioral interventions, neurofeedback, cognitive training, and restricted elimination diets before they can be supported as treatments for core ADHD symptoms.
Nature Genetics | 2012
Josephine Elia; Joseph T. Glessner; Kai Wang; Nagahide Takahashi; Corina Shtir; Dexter Hadley; Patrick Sleiman; Haitao Zhang; Cecilia E. Kim; Reid J. Robison; Gholson J. Lyon; James H. Flory; Jonathan P. Bradfield; Marcin Imielinski; Cuiping Hou; Edward C. Frackelton; Rosetta M. Chiavacci; Takeshi Sakurai; Cara Rabin; Frank A. Middleton; Kelly Thomas; Maria Garris; Frank D. Mentch; Christine M. Freitag; Hans-Christoph Steinhausen; Alexandre A. Todorov; Andreas Reif; Aribert Rothenberger; Barbara Franke; Eric Mick
Attention deficit hyperactivity disorder (ADHD) is a common, heritable neuropsychiatric disorder of unknown etiology. We performed a whole-genome copy number variation (CNV) study on 1,013 cases with ADHD and 4,105 healthy children of European ancestry using 550,000 SNPs. We evaluated statistically significant findings in multiple independent cohorts, with a total of 2,493 cases with ADHD and 9,222 controls of European ancestry, using matched platforms. CNVs affecting metabotropic glutamate receptor genes were enriched across all cohorts (P = 2.1 × 10−9). We saw GRM5 (encoding glutamate receptor, metabotropic 5) deletions in ten cases and one control (P = 1.36 × 10−6). We saw GRM7 deletions in six cases, and we saw GRM8 deletions in eight cases and no controls. GRM1 was duplicated in eight cases. We experimentally validated the observed variants using quantitative RT-PCR. A gene network analysis showed that genes interacting with the genes in the GRM family are enriched for CNVs in ∼10% of the cases (P = 4.38 × 10−10) after correction for occurrence in the controls. We identified rare recurrent CNVs affecting glutamatergic neurotransmission genes that were overrepresented in multiple ADHD cohorts.
American Journal of Psychiatry | 2012
Nigel Melville Williams; Barbara Franke; Eric Mick; Richard Anney; Christine M. Freitag; Michael Gill; Anita Thapar; Michael Conlon O'Donovan; Michael John Owen; Peter Holmans; Lindsey Kent; Frank A. Middleton; Yanli Zhang-James; Lu Liu; Jobst Meyer; T. T. Nguyen; Jasmin Romanos; Marcel Romanos; Christiane Seitz; Tobias J. Renner; Susanne Walitza; Andreas Warnke; Haukur Palmason; Jan Buitelaar; Nanda Rommelse; Alejandro Arias Vasquez; Ziarih Hawi; Kate Langley; Joseph A. Sergeant; Hans-Christoph Steinhausen
Objective: Attention deficit hyperactivity disorder (ADHD) is a common, highly heritable psychiatric disorder. Because of its multifactorial etiology, however, identifying the genes involved has been difficult. The authors followed up on recent findings suggesting that rare copy number variants (CNVs) may be important for ADHD etiology. Method: The authors performed a genome-wide analysis of large, rare CNVs (<1% population frequency) in children with ADHD (N=896) and comparison subjects (N=2,455) from the IMAGE II Consortium. Results: The authors observed 1,562 individually rare CNVs >100 kb in size, which segregated into 912 independent loci. Overall, the rate of rare CNVs >100 kb was 1.15 times higher in ADHD case subjects relative to comparison subjects, with duplications spanning known genes showing a 1.2-fold enrichment. In accordance with a previous study, rare CNVs >500 kb showed the greatest enrichment (1.28-fold). CNVs identified in ADHD case subjects were significantly enriched for loci implicated in autism and in schizophrenia. Duplications spanning the CHRNA7 gene at chromosome 15q13.3 were associated with ADHD in single-locus analysis. This finding was consistently replicated in an additional 2,242 ADHD case subjects and 8,552 comparison subjects from four independent cohorts from the United Kingdom, the United States, and Canada. Presence of the duplication at 15q13.3 appeared to be associated with comorbid conduct disorder. Conclusions: These findings support the enrichment of large, rare CNVs in ADHD and implicate duplications at 15q13.3 as a novel risk factor for ADHD. With a frequency of 0.6% in the populations investigated and a relatively large effect size (odds ratio=2.22, 95% confidence interval=1.5–3.6), this locus could be an important contributor to ADHD etiology.
Journal of Autism and Developmental Disorders | 2009
Aisling Mulligan; Richard Anney; Myra O'Regan; Wai Chen; Louise Butler; Michael Fitzgerald; Jan Buitelaar; Hans-Christoph Steinhausen; Aribert Rothenberger; Ruud B. Minderaa; Judith S. Nijmeijer; Pieter J. Hoekstra; Robert D. Oades; Herbert Roeyers; Cathelijne J. M. Buschgens; Hanna Christiansen; Barbara Franke; Isabel Gabriëls; Catharina A. Hartman; Jonna Kuntsi; Rafaela Marco; Sheera Meidad; Ueli Mueller; Lamprini Psychogiou; Nanda Rommelse; Margaret Thompson; Henrik Uebel; Tobias Banaschewski; R. Ebstein; Jacques Eisenberg
It is hypothesised that autism symptoms are present in Attention-Deficit/Hyperactivity Disorder (ADHD), are familial and index subtypes of ADHD. Autism symptoms were compared in 821 ADHD probands, 1050 siblings and 149 controls. Shared familiality of autism symptoms and ADHD was calculated using DeFries-Fulker analysis. Autism symptoms were higher in probands than siblings or controls, and higher in male siblings than male controls. Autism symptoms were familial, partly shared with familiality of ADHD in males. Latent class analysis using SCQ-score yielded five classes; Class 1(31%) had few autism symptoms and low comorbidity; Classes 2–4 were intermediate; Class 5(7%) had high autism symptoms and comorbidity. Thus autism symptoms in ADHD represent a familial trait associated with increased neurodevelopmental and oppositional/conduct disorders.
Journal of the American Academy of Child and Adolescent Psychiatry | 2015
Samuele Cortese; Maite Ferrin; Daniel Brandeis; Jan Buitelaar; David Daley; Ralf W. Dittmann; Martin Holtmann; Paramala Santosh; Jim Stevenson; Argyris Stringaris; Alessandro Zuddas; Edmund Sonuga-Barke
Objective The authors performed meta-analyses of randomized controlled trials to examine the effects of cognitive training on attention-deficit/hyperactivity disorder (ADHD) symptoms, neuropsychological deficits, and academic skills in children/adolescents with ADHD. Method The authors searched Pubmed, Ovid, Web of Science, ERIC, and CINAHAL databases through May 18, 2014. Data were aggregated using random-effects models. Studies were evaluated with the Cochrane risk of bias tool. Results Sixteen of 695 nonduplicate records were analyzed (759 children with ADHD). When all types of training were considered together, there were significant effects on total ADHD (standardized mean difference [SMD] = 0.37, 95% CI = 0.09–0.66) and inattentive symptoms (SMD = 0.47, 95% CI = 0.14–0.80) for reports by raters most proximal to the treatment setting (i.e., typically unblinded). These figures decreased substantially when the outcomes were provided by probably blinded raters (ADHD total: SMD = 0.20, 95% CI = 0.01–0.40; inattention: SMD = 0.32, 95% CI = −0.01 to 0.66). Effects on hyperactivity/impulsivity symptoms were not significant. There were significant effects on laboratory tests of working memory (verbal: SMD = 0.52, 95% CI = 0.24–0.80; visual: SMD = 0.47, 95% CI = 0.23–0.70) and parent ratings of executive function (SMD = 0.35, 95% CI = 0.08–0.61). Effects on academic performance were not statistically significant. There were no effects of working memory training, specifically on ADHD symptoms. Interventions targeting multiple neuropsychological deficits had large effects on ADHD symptoms rated by most proximal assessors (SMD = 0.79, 95% CI = 0.46–1.12). Conclusion Despite improving working memory performance, cognitive training had limited effects on ADHD symptoms according to assessments based on blinded measures. Approaches targeting multiple neuropsychological processes may optimize the transfer of effects from cognitive deficits to clinical symptoms.
Journal of Child Psychology and Psychiatry | 2013
Samuele Cortese; Martin Holtmann; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Ralf W. Dittmann; John Graham; Eric Taylor; Joseph A. Sergeant
BACKGROUNDnMedication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD.nnnMETHODSnFor ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system.nnnRESULTSnThe review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms.nnnCONCLUSIONnMost AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment.
Archives of General Psychiatry | 2010
Jonna Kuntsi; Alexis C. Wood; Fruehling V. Rijsdijk; Katherine A. Johnson; Penelope Andreou; Bjoern Albrecht; Alejandro Arias-Vasquez; Jan Buitelaar; Gráinne McLoughlin; Nanda Rommelse; Joseph A. Sergeant; Edmund Sonuga-Barke; Henrik Uebel; Jaap J. van der Meere; Tobias Banaschewski; Michael Gill; Iris Manor; Ana Miranda; Fernando Mulas; Robert D. Oades; Herbert Roeyers; Aribert Rothenberger; Hans-Christoph Steinhausen; Stephen V. Faraone; Philip Asherson
CONTEXTnAttention-deficit/hyperactivity disorder (ADHD) is associated with widespread cognitive impairments, but it is not known whether the apparent multiple impairments share etiological roots or separate etiological pathways exist. A better understanding of the etiological pathways is important for the development of targeted interventions and for identification of suitable intermediate phenotypes for molecular genetic investigations.nnnOBJECTIVESnTo determine, by using a multivariate familial factor analysis approach, whether 1 or more familial factors underlie the slow and variable reaction times, impaired response inhibition, and choice impulsivity associated with ADHD.nnnDESIGNnAn ADHD and control sibling-pair design.nnnSETTINGnBelgium, Germany, Ireland, Israel, Spain, Switzerland, and the United Kingdom.nnnPARTICIPANTSnA total of 1265 participants, aged 6 to 18 years: 464 probands with ADHD and 456 of their siblings (524 with combined-subtype ADHD), and 345 control participants.nnnMAIN OUTCOME MEASURESnPerformance on a 4-choice reaction time task, a go/no-go inhibition task, and a choice-delay task.nnnRESULTSnThe final model consisted of 2 familial factors. The larger factor, reflecting 85% of the familial variance of ADHD, captured 98% to 100% of the familial influences on mean reaction time and reaction time variability. The second, smaller factor, reflecting 13% of the familial variance of ADHD, captured 62% to 82% of the familial influences on commission and omission errors on the go/no-go task. Choice impulsivity was excluded in the final model because of poor fit.nnnCONCLUSIONSnThe findings suggest the existence of 2 familial pathways to cognitive impairments in ADHD and indicate promising cognitive targets for future molecular genetic investigations. The familial distinction between the 2 cognitive impairments is consistent with recent theoretical models--a developmental model and an arousal-attention model--of 2 separable underlying processes in ADHD. Future research that tests the familial model within a developmental framework may inform developmentally sensitive interventions.
Journal of the American Academy of Child and Adolescent Psychiatry | 2010
Benjamin M. Neale; Sarah E. Medland; Stephan Ripke; Richard Anney; Philip Asherson; Jan Buitelaar; Barbara Franke; Michael Gill; Lindsey Kent; Peter Holmans; Frank A. Middleton; Anita Thapar; Klaus-Peter Lesch; Stephen V. Faraone; Mark J. Daly; Thuy Trang Nguyen; Helmut Schäfer; Hans-Christoph Steinhausen; Andreas Reif; Tobias J. Renner; Marcel Romanos; Jasmin Romanos; Andreas Warnke; Susanne Walitza; Christine M. Freitag; Jobst Meyer; Haukur Palmason; Aribert Rothenberger; Ziarih Hawi; Joseph A. Sergeant
OBJECTIVEnAlthough twin and family studies have shown attention-deficit/hyperactivity disorder (ADHD) to be highly heritable, genetic variants influencing the trait at a genome-wide significant level have yet to be identified. Thus additional genomewide association studies (GWAS) are needed.nnnMETHODnWe used case-control analyses of 896 cases with DSM-IV ADHD genotyped using the Affymetrix 5.0 array and 2,455 repository controls screened for psychotic and bipolar symptoms genotyped using Affymetrix 6.0 arrays. A consensus SNP set was imputed using BEAGLE 3.0, resulting in an analysis dataset of 1,033,244 SNPs. Data were analyzed using a generalized linear model.nnnRESULTSnNo genome-wide significant associations were found. The most significant results implicated the following genes: PRKG1, FLNC, TCERG1L, PPM1H, NXPH1, PPM1H, CDH13, HK1, and HKDC1.nnnCONCLUSIONSnThe current analyses are a useful addition to the present literature and will make a valuable contribution to future meta-analyses. The candidate gene findings are consistent with a prior meta-analysis in suggesting that the effects of ADHD risk variants must, individually, be very small and/or include multiple rare alleles.
Final version in: Journal of Autism and Developmental Disorders : devoted to all severe psychopathologies in childhood., 39 (2009) ; no. 2, p. 197-211 / DOI 10.1007/s10803-008-0621-3 | 2011
Aisling Mulligan; Richard Anney; Myra O’Regan; Louise Butler; Michael Fitzgerald; Jan Buitelaar; Hans-Christoph Steinhausen; Aribert Rothenberger; Ruud B. Minderaa; Judith S. Nijmeijer; Pieter J. Hoekstra; Robert D. Oades; Herbert Roeyers; Cathelijne J. M. Buschgens; Hanna Christiansen; Barbara Franke; Isabel Gabriëls; Catharina A. Hartman; Jonna Kuntsi; Rafaela Marco; Sheera Meidad; Ueli C Müller; Lamprini Psychogiou; Nanda Rommelse; Margaret Thompson; Henrik Uebel; Tobias Banaschewski; Richard P. Ebstein; Jacques Eisenberg; Iris Manor
It is hypothesised that autism symptoms are present in Attention-Deficit/Hyperactivity Disorder (ADHD), are familial and index subtypes of ADHD. Autism symptoms were compared in 821 ADHD probands, 1050 siblings and 149 controls. Shared familiality of autism symptoms and ADHD was calculated using DeFries-Fulker analysis. Autism symptoms were higher in probands than siblings or controls, and higher in male siblings than male controls. Autism symptoms were familial, partly shared with familiality of ADHD in males. Latent class analysis using SCQ-score yielded five classes; Class 1(31%) had few autism symptoms and low comorbidity; Classes 2–4 were intermediate; Class 5(7%) had high autism symptoms and comorbidity. Thus autism symptoms in ADHD represent a familial trait associated with increased neurodevelopmental and oppositional/conduct disorders.
American Journal of Psychiatry | 2013
Marian Lindsay Hamshere; Kate Langley; Joanna Martin; Sharifah Shameem Agha; Evangelia Stergiakouli; Richard Anney; Jan Buitelaar; Stephen V. Faraone; Klaus-Peter Lesch; Benjamin M. Neale; Barbara Franke; Edmund Sonuga-Barke; Philip Asherson; Andrew Merwood; Jonna Kuntsi; Sarah E. Medland; Stephan Ripke; Hans-Christoph Steinhausen; Christine M. Freitag; Andreas Reif; Tobias J. Renner; Marcel Romanos; Jasmin Romanos; Andreas Warnke; Jobst Meyer; Haukur Palmason; Alejandro Arias Vasquez; Nanda Lambregts-Rommelse; Herbert Roeyers; Joseph Biederman
Objective Although attention deficit hyperactivity disorder (ADHD) is highly heritable, genome-wide association studies (GWAS) have not yet identified any common genetic variants that contribute to risk. There is evidence that aggression or conduct disorder in children with ADHD indexes higher genetic loading and clinical severity. The authors examine whether common genetic variants considered en masse as polygenic scores for ADHD are especially enriched in children with comorbid conduct disorder. Method Polygenic scores derived from an ADHD GWAS meta-analysis were calculated in an independent ADHD sample (452 case subjects, 5,081 comparison subjects). Multivariate logistic regression analyses were employed to compare polygenic scores in the ADHD and comparison groups and test for higher scores in ADHD case subjects with comorbid conduct disorder relative to comparison subjects and relative to those without comorbid conduct disorder. Association with symptom scores was tested using linear regression. Results Polygenic risk for ADHD, derived from the meta-analysis, was higher in the independent ADHD group than in the comparison group. Polygenic score was significantly higher in ADHD case subjects with conduct disorder relative to ADHD case subjects without conduct disorder. ADHD polygenic score showed significant association with comorbid conduct disorder symptoms. This relationship was explained by the aggression items. Conclusions Common genetic variation is relevant to ADHD, especially in individuals with comorbid aggression. The findings suggest that the previously published ADHD GWAS meta-analysis contains weak but true associations with common variants, support for which falls below genome-wide significance levels. The findings also highlight the fact that aggression in ADHD indexes genetic as well as clinical severity.